Posts filed under: News

MELBOURNE, Australia & NANTES, France, 16 April 2018 – Telix announced a research partnership with the French National Institute of Health and Medical Research (INSERM)  and the “Accelerator for Research in...
Continue Reading →
MELBOURNE, Australia, 10 April 2018 – Telix Pharmaceuticals is disclosing that a controlled entity of Telix has entered into a material contract with Endocyte, Inc. More details can be accessed...
Continue Reading →
MELBOURNE Australia, 28 March 2018 – Telix Pharmaceuticals is pleased to provide this update on the Company’s prostate imaging program. For full details click here.    ...
Continue Reading →
MELBOURNE & INDIANAPOLIS,  26 March 2018 – Telix Pharmaceuticals announced the submission of a Drug Master File (DMF) for a sterile kit used in the preparation of 68Ga-PSMA-11 (PSMA Kit),...
Continue Reading →
SYDNEY, April 4 2018 – Telix Pharmaceuticals gets a mention in the CLSA M&A Outlook for the Australian healthcare sector. Great to get a mention alongside some very notable Aussie biotech,...
Continue Reading →
MELBOURNE, Australia & NIJMEGAN, The Netherlands, March 15 2018 – Telix Pharmaceuticals Ltd has today announced a clinical collaboration with Radboud University Medical Centre. To read the full media release...
Continue Reading →
BioSpectrum Asia interviews Telix Japan President & COO Dr Shintaro Nishimura on APAC oncology market & opportunities/challenges in Japanese market for radiopharmaceutical products. To read the full article  click here....
Continue Reading →
Melbourne & Brussels March 1 2018 – Telix Pharmaceuticals Ltd has today announced the appointment of Ms Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European operations. See...
Continue Reading →
Melbourne, Australia, Feb. 26 2018 – Telix Pharmaceuticals Limited is pleased to provide its Annual Report 2017, released today. For more information click here – Annual Report 2017  ...
Continue Reading →
Melbourne, Australia, Feb. 21 2018 – Telix Pharmaceuticals Limited is pleased to provide this shareholder update.  This update is a 3 month post-IPO update, released in concert with end of...
Continue Reading →